A RANDOMIZED PHASE II DOUBLE-BLIND TRIAL OF SUNITINIB VERSUS PLACEBO IN COMBINATION WITH LANREOTIDE IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC MIDGUT CARCINOID TUMORS
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Jan 2019
At a glance
- Drugs Sunitinib (Primary) ; Lanreotide
- Indications Carcinoid tumour
- Focus Therapeutic Use
- Acronyms SUNLAND
- 30 Jan 2017 Planned End Date changed from 1 Mar 2017 to 1 Dec 2017.
- 30 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
- 21 Dec 2016 Status changed from recruiting to active, no longer recruiting.